New study has demonstrated that markers of insulin sensitivity and blood glucose are improved among women on hormone therapy.
Hormone therapy was found to decrease the number of metabolites that are directly associated with type 2 diabetes, revealed new study based on WHI data. Study results will be presented during The North American Menopause Society (NAMS) Annual Meeting in Chicago, September 25 to 28, 2019. In the WHI trials, the incidence of diabetes was reduced with the use of hormone therapy, particularly combined estrogen and progestin therapy. The new study utilized data from a prior study which measured approximately 370 metabolites on 1,362 women involved in the WHI.
Researchers in the current study selected nine metabolites that were previously found to be strongly associated with the development of Type 2 diabetes in other studies to see if they were affected by randomized hormone therapy.
Of the nine targeted metabolites, seven were significantly decreased with the use of hormone therapy consisting of a combination of estrogen and progestin.
"Interestingly, we found that the decreases were more pronounced with the use of estrogen and progestin combined than with estrogen alone," says Dr. Heather Hirsch, lead author of the study from The Ohio State University Medical Center. "This result parallels the findings from the WHI on the effect of hormone therapy on the incidence of type 2 diabetes."
Drs. Hirsch and Faubion are available for interviews before the presentation at the Annual Meeting.
For more information on menopause and healthy aging, visit menopause.org.
Advertisement
Source-Eurekalert